Sanofi ODYSSEY Clinical Trial
Are you eligible for the Sanofi ODYSSEY Clinical Trial? The ODYSSEY clinical trial program is a collection of studies investigating the safety, tolerability and efficacy of an investigational drug for patients with high cholesterol who are at risk for cardiovascular disease and not adequately controlled by their current lipid modifying therapy. This program has been developed and sponsored by Sanofi US Services Inc. and Regeneron Pharmaceuticals Inc. who have extensive experience in researching and developing new medicines for the treatment of serious medical conditions.
Cardiovascular disease (CVD) (including atherosclerosis and coronary heart disease) is the leading cause of death and disability in the United States. Reducing LDL-cholesterol levels remains the main goal when managing high cholesterol and, with current therapy, such as statins, can be effective at reducing the risk of CVD. However, despite the availability of such well-established treatments, some people are still not reaching their LDL-cholesterol goals set by the recommended guidelines. The ODYSSEY phase 3 clinical research study program is being done to see if this new investigational medication can help further reduce LDL-cholesterol and provide additional options for people in the future.
The initial criteria are:
- Aged 40 years and older who have recently been hospitalized for acute coronary syndrome (obstructed coronary arteries) not adequately controlled by statins
- Baseline entry: LDL-C ≥ 70 mg/dL (≥1.81mmol/L)
If you are interested in taking part in one of the ODYSSEY phase 3 clinical research studies– or know someone who may want to take part, please: